Rockville, MD – According to filings with the U.S. Securities and Exchange Commission, Vigene Biosciences is raising $2,999,996.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Zairen Sun played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Vigene Biosciences

Vigene Biosciences was founded in 2012 by senior scientists with expertise in the fields of virology and gene therapy. At Vigene, we strive to be the leading supplier of gene delivery technologies with the mission to advance biomedical research and to make gene therapy affordable. We offer both research-grade and cGMP-grade AAV, lentivirus, and adenovirus-based products and custom services. Some of our product offerings include ready-to-ship genome wide human cDNA ORFs on adenoviral or lentiviral vectors, AAV shRNA constructs, pre-made control GFP viruses, AAV biosensors developed in partnership with Janelia Research Campus, AAV alpha-synuclein vectors developed in partnership with The Michael J Fox Foundation, and many others.

To learn more about Vigene Biosciences, visit http://www.vigenebio.com/

Contact:
Zairen Sun, Chief Executive Officer
301-251-6638
zsun@vigenebio.com

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved